On March 9, 2022 Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, reported two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in New Orleans, La., from April 8-13, 2022 (Press release, Palleon Pharmaceuticals, MAR 9, 2022, View Source [SID1234609812]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Palleon will present an assessment of the safety, pharmacokinetics, and pharmacodynamics of E-602, the company’s first-in-class immuno-oncology drug candidate, in non-human primates. Those studies found that E-602 exhibits sustained, dose-dependent pharmacodynamic effects on desialylation of immune cells and a wide safety margin.

Additionally, Palleon will present data on the company’s novel bifunctional PD-L1-targeted sialidase. Studies performed in a transgenic mouse model of colon cancer expressing PD-L1 found that the bifunctional PD-L1-targeted sialidase exhibited enhanced efficacy compared to E-602 and to an anti-PD-L1 antibody, as well as dose-dependent tumor growth inhibition and modulation of immune cell infiltration.

Details of the poster presentations are as follows:

Title: Assessment of the safety, pharmacokinetics, and pharmacodynamics of a first-in-class cancer drug candidate E-602, a sialoglycan degrader, in non-human primates
Number: LB203
Timing: April 13, 2022, 9:00 a.m. – 12:30 p.m. CDT

Title: Development of PD-L1-targeted sialidase as a novel cancer immunotherapeutic approach
Number: LB221
Timing: April 13, 2022, 9:00 a.m. – 12:30 p.m. CDT